Current Report Filing (8-k)
April 15 2019 - 3:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 12, 2019
RELMADA THERAPEUTICS, INC.
(Exact name of registrant as specified in its
charter)
Nevada
|
|
333-184881
|
|
45-5401931
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
880 Third Avenue, 12
th
Floor
New York, NY
|
|
10022
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code
(212) 547-9591
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive
Agreement.
On April 15, 2019, Relmada
Therapeutics, Inc. (the “Company”) executed an amendment to the Company’s 2014 Stock Option and Equity Incentive
Plan, as amended (the “
Plan Amendment
”). The Plan Amendment increases the number of shares of common stock that
the Company is authorized to issue under the plan to 10,111,718 shares.
As previously disclosed
in Item 5.07 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 28, 2019, the Plan
Amendment was approved by the Company’s stockholders at the 2018 annual meeting of stockholders held on February 27, 2019.
The foregoing description of the Plan Amendment does not purport to be complete and is qualified in its entirety by reference
to the full text of the Plan Amendment, a copy of which will be filed as an exhibit to our Form 10-Q for the quarter ended March
31, 2019.
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
On April 12, 2019, the
Company filed a Certificate of Amendment to its Articles of Incorporation, as amended, with the Secretary of State of Nevada to
increase the number of authorized shares of the Company’s common stock from 100,000,000 to 200,000,000 shares (the “
Charter
Amendment
”).
As previously disclosed
in Item 5.07 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 28, 2019, the Charter
Amendment was approved by the Company’s stockholders at the 2018 annual meeting of stockholders held on February 27, 2019.
The foregoing description of the Charter Amendment does not purport to be complete and is qualified in its entirety by reference
to the full text of the Charter Amendment, a copy of which will be filed as an exhibit to our Form 10-Q for the quarter ended March
31, 2019.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: April 15, 2019
|
RELMADA THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/ Sergio Traversa
|
|
Name:
|
Sergio Traversa
|
|
Title:
|
Chief Executive Officer
|